Could Abbott Laboratories (NYSE:ABT) See a Reversal After More Sellers Came In?

Abbott Laboratories (NYSE:ABT) Logo

Investors sentiment decreased to 0.82 in 2019 Q1. Its down 0.09, from 0.91 in 2018Q4. It fall, as 52 investors sold Abbott Laboratories shares while 617 reduced holdings. 143 funds opened positions while 408 raised stakes. 1.26 billion shares or 2.74% less from 1.29 billion shares in 2018Q4 were reported.
Regent Investment Mngmt Ltd Liability Corp invested in 27,961 shares. Barr E S invested in 0.05% or 6,024 shares. Altfest L J & Incorporated owns 2,670 shares or 0.18% of their US portfolio. Finance Advantage stated it has 0% in Abbott Laboratories (NYSE:ABT). Manufacturers Life Ins Comm The has invested 0.32% in Abbott Laboratories (NYSE:ABT). Investec Asset Limited has 2,906 shares for 0% of their portfolio. Parsec Finance Mngmt Inc holds 233,786 shares. Hendley & Co stated it has 42,089 shares or 1.72% of all its holdings. First Fincl In invested in 22,477 shares or 1.34% of the stock. Moreover, Park National Corp Oh has 2.47% invested in Abbott Laboratories (NYSE:ABT). First Commonwealth Corporation Pa invested 0.3% of its portfolio in Abbott Laboratories (NYSE:ABT). Central Retail Bank And Co reported 0.1% of its portfolio in Abbott Laboratories (NYSE:ABT). Lombard Odier Asset (Europe) Limited invested 0.14% in Abbott Laboratories (NYSE:ABT). Sivik Global Ltd owns 100,000 shares. Cambridge invested in 0.34% or 70,300 shares.

Since January 30, 2019, it had 1 buy, and 1 sale for $12.17 million activity. Stratton John G bought $249,875 worth of stock or 3,455 shares.

The stock of Abbott Laboratories (NYSE:ABT) registered an increase of 0.06% in short interest. ABT’s total short interest was 15.22M shares in July as published by FINRA. Its up 0.06% from 15.21M shares, reported previously. With 5.71M shares average volume, it will take short sellers 3 days to cover their ABT’s short positions.

The stock decreased 1.79% or $1.53 during the last trading session, reaching $83.92. About 5.53 million shares traded or 4.37% up from the average. Abbott Laboratories (NYSE:ABT) has risen 23.36% since July 14, 2018 and is uptrending. It has outperformed by 18.93% the S&P500.

Abbott Laboratories manufactures and sells health care products worldwide. The company has market cap of $148.05 billion. The companyÂ’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon. It has a 56.93 P/E ratio. The Company’s Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic tests; informatics and automation solutions; and a suite of informatics tools and professional services.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Among 2 analysts covering Abbott Labs (NYSE:ABT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abbott Labs has $9100 highest and $84 lowest target. $87’s average target is 3.67% above currents $83.92 stock price. Abbott Labs had 10 analyst reports since March 1, 2019 according to SRatingsIntel. The stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by Cowen & Co on Thursday, March 14. The rating was maintained by Barclays Capital on Friday, March 8 with “Buy”. Wells Fargo maintained the stock with “Outperform” rating in Thursday, June 13 report.

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: Forbes.com which released: “How Does Abbott’s Established Pharmaceuticals Business Compare With Its Peers? – Forbes” on June 26, 2019, also Fool.com with their article: “Abbott Labs Stock Just Hit an All-Time High: Buy, Sell, or Hold? – The Motley Fool” published on June 18, 2019, Gurufocus.com published: “3 Dividend Stocks Retirees Must Have in Their Portfolios – GuruFocus.com” on July 08, 2019. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: Finance.Yahoo.com and their article: “Should Abbott Laboratories (NYSE:ABT) Be Part Of Your Dividend Portfolio? – Yahoo Finance” published on May 18, 2019 as well as Seekingalpha.com‘s news article titled: “Hunting For The Right Dividend Stock – Seeking Alpha” with publication date: July 07, 2019.

Abbott Laboratories (NYSE:ABT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.